419 results about "Low Grade Malignant Neoplasm" patented technology

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant tumor. A method for treating a human patient having a non-resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition to the patient and treating the patient with effective non-surgical medical methodologies to diminish the tumor. An article of manufacture combines an α-interferon composition within a packaging material and a package label or insert indicating that administration of an immunostimulatory dosage of an α-interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having the malignant tumor.

The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.

To detect a malignant tumor more accurately by detecting a feature of a cancerous tumor pulsation more appropriately, a tissue malignant tumor detection method according to the present invention includes: segmenting, into blocks, a region scanned with ultrasound (S100); estimating, based on a scan signal, a tissue pulsation that is a temporal variation in tissue displacement derived from pulsations of a tissue (S101); extracting, for each of the blocks, pulsation-related features that are parameters related to the tissue pulsation (S103); calculating distribution characteristics of the pulsation-related features for each of the blocks (S104); and classifying, based on the distribution characteristics, whether or not each of the blocks is a malignant block that is a block including the malignant tumor (S105).

The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions.

The invention discloses particulates with double functions of internal radiotherapy and thermal therapy, and a preparation method thereof. The particulates are mainly compounded and formed by glass containing radioactive species yttrium-90 or / and phosphorus-32, and solid ferrite with magnetocaloric effect. When the particulates intervene in vivo, the radioactive species yttrium-90 or / and the phosphorus-32 contained in the glass can release Beta rays in vivo to kill cancer cells intervening in surrounding tissues without damaging the distant healthy tissues; the solid ferrite has good hysteresis exothermicity and can transform exosomatic magnetic energy into heat energy so as to release heat under the action of an external alternating magnetic field, so that the temperature around the tumor area can raise to 43 to 47 DEG C within a short time, and tumour cells intervening in the surrounding tissues are burnt and killed without influencing normal cells with better heat tolerance, thereby realizing the purpose of treating tumor by combining the internal radiotherapy and the thermotherapy, and having double lethality to cancer cells. The method for combining the radiation treatment and the heat treatment is an indispensable supplementary therapy means to treat the malignant tumor with chemical drug resistance. In addition, the particulates have good chemical stability and biocompatibility, and have great application prospect in the aspect of treating the malignant tumor.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

A method and kit is provided to quantifying and qualifying exosomes in human cell derived samples or in body fluid based on expression of TM9-superfamily proteins on the exosomes. Furthermore, a method and a kit to diagnose malignant tumors is provided. The disclosure also provides a method to monitor tumor growth.

The invention discloses a beta-carboline ruthenium compound. The molecular formula of the beta-carboline ruthenium compound is [Ru (N^N) 2 (Nh) XClY] (A^A)z, wherein N^N is selected from bpy or phen; A^A is selected from PF6 or SO3CF3; X is equal to 1 or 2, Y is equal to 2-X, and Z is equal to 1 or 2; or the molecular formula of the beta-carboline ruthenium compound is [Ru (N^N) 2 (1-Py-betaC)] (PF^)2, wherein N^N is selected from bpy, phen or DIP. On a molecular mechanism, the invention proves that the beta-carboline ruthenium compound can be used for treating cancers and has a better effectthan the effects of that of the traditional metal compound cisplatin with wide application and ruthenium compounds NAMI-A in clinical tests; . Thethe beta-carboline ruthenium compound for treating the cancers as an autophagic cell inducer fills the blank of the prior art and develops a new line for developing a new generation of high-efficiency medicaments for treating malignant tumors.

The invention discloses a gold nanorods based drug carrier. The carrier is characterized in that: gold nanorods is wrapped with a polyanion film layer, a polycation film layer and an hTERT gene antisense oligonucleotide layer from inside to outside. The gold nanorods based drug carrier is prepared by the layer-by-layer self-assembly principle by utilizing the electrostatic force among radicals, and can be used for preparing inhibitors for malignant tumor cell telomerase. The invention causes hTERT gene antisense oligonucleotide to be loaded on the gold nanorods for the first time to solve the problem of low transfection rate occurred in naked antisense oligonucleotide. The prepared gold nanorods based drug carrier does not only has the advantages of high transfection rate, strong targeting property, obvious effect of inhibiting the activity of the malignant tumor cell telomerase, and the like, but also has the advantages of safety and innocuity, which opens up a new way for the application of the gold nanorods in the biomedicine field; in addition, the invention has the advantages of simple operation for the preparation technology and low cost, and is suitable for scale production.

A method of detecting and diagnosing cancers characterized by the presence of at least one nodule / neoplasm from an imaging scan is presented. To detect nodules in an imaging scan, a 3D CNN using a single feed forward pass of a single network is used. After detection, risk stratification is performed using a supervised or an unsupervised deep learning method to assist in characterizing the detected nodule / neoplasm as benign or malignant. The supervised learning method relies on a 3D CNN used with transfer learning and a graph regularized sparse MTL to determine malignancy. The unsupervised learning method uses clustering to generate labels after which label proportions are used with a novel algorithm to classify malignancy. The method assists radiologists in improving detection rates of lung nodules to facilitate early detection and minimizing errors in diagnosis.

The chemotherapy of malignant tumours is greatly restricted by the generally slight differentiation of the available cytostatic agents between normal and malignant tissue. In order to achieve an improvement of the selectivity in cancer therapy, novel prodrugs have been developed from 6-hydroxy-2,3-dihydro-1H-indolene, 5-hydroxy-1,2-dihydro-3H-pyrrolo[3,2-e]indolene and 5-hydroxy-1,2-dihydro-3H-benzo[e]indolene as well as from 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]-quinolines, that may be used within the framework of the ADEP therapy (antibody directed enzyme prodrug therapy). The new prodrugs are characterised by a high difference in toxicity between the prodrug and underlying drug and by a very high efficacy of the drug. The high selectivity of the new prodrugs is probably attributed to the fact that, in the new prodrugs, a secondary halide is present in contrast to the prodrugs of a similar type previously produced by us. The direct alkylation of the DNA or RNA by the prodrugs and thus the toxicity of the prodrugs is thereby reduced. After splitting off of the glycosidic and / or acetal group on the phenolic hydroxy groups of the prodrugs, a spirocyclopropacyclohexadiene is formed which, being a highly toxic group, effects an alkylation of the DNA or RNA.

The invention discloses active extracts of rosa roxburghii tratt fruit, and a preparation method, a detection method and application thereof. The preparation method comprises the following steps of: extracting rosa roxburghii tratt fruit by conventional processes; filtering to remove rosa roxburghii tratt residues; concentrating the filtered solution at the reduced pressure; extracting with an organic solvent; recovering the organic solvent; adding water for dispersing; filtering; washing with water for depositing; mixing the filtered solutions; and respectively drying the filtered solution and the deposit to respectively obtain an active extract B and an active extract A. The preparation method provided by the invention solves the problems of extraction, enrichment and refinement of effective active components in the rosa roxburghii tratt, and industrial production is easy to realize by the preparation process; the detection method provided by the invention can effectively ensure thequality of the active extracts; and the obtained active extracts have obvious anti-malignant tumor activity, have synergistic action with clinical anti-cancer drugs, have better alpha-glucosidase inhibition activity, can be used for preparing drugs and adjuvant drugs for treating malignant tumors or used as health food additives, can also be used for preparing drugs and health products for preventing or treating diabetes or used as food additives, and have higher application values and good application prospects.

The invention provides preparation of mesothelin chimeric antigen receptor modified T cells and application of the T cells in pancreatic cancer treatment, discloses a chimeric antigen receptor, particularly relates to a chimeric antigen receptor which serves as a guiding sequence by combining a granulocyte-macrophage cluster stimulating factor receptor, and further relates to the T cells expressing the chimeric antigen receptor. The T cells can kill tumor cells highly expressing mesothelin in a targeted mode and have the application of preparing drugs for treating pancreatic cancer malignant tumors and virus infective diseases.

The invention provides an application of mitoxantrone and salt thereof as a lymph tracer (such as hydrochloric acid mitoxantrone, oxalic acid mitoxantrone, sulfuric acid mitoxantrone, phosphoric acid mitoxantrone, acetic acid mitoxantrone, citric acid mitoxantrone and the like). The mitoxantrone and salt thereof can be used for preparing injection, powder injection, emulsion, liposome, nanoparticle, microballoon and the like. The mitoxantrone and salt thereof not only can be used for killing malignant tumor cells, but also the blue dye feature can be used as the lymph tracer applied to lymphadenectomy in cancer operative treatment, which is suitable for treating stomach cancer, breast cancer, intestinal cancer, cervical carcinoma, testis cancer and the like.

The invention relates to a bufalin derivative having a structure represented as a general formula I, wherein R is selected from one of the following structure groups as shown in the specification, or pharmaceutically acceptable salt, as well as a preparation method, a pharmaceutical composition and application of the derivative. The bufalin derivative has an activity on inhibiting tumor cell lines, and can be used as a medicine for treating malignant tumors.

The invention relates to a polypeptide with tumor-targeting performance and a preparation method. The structure of the aminophenol sequence of the polypeptide is CASPSGALRSC or CFPVPGHDLVC or CFSVPGHDIVC or CTPMSLSLSEC or CYTYPLGWHIC. The pC89 phage peptide library expressing protein polypeptides with different sequences of 108 and human breast cancer cell lines MDA-MB-231 are repetitively cocultured for a few times; filtration can penetrate cell membrane to enter into the phages expressing specific polypeptide in cytolymph and / or karyon, and phages are amplified in vitro in order to carry out DNA sequencing and deduce an exogenous amino acid sequence inserted in the phages; the filtered specific polypeptide phages, other human tumor cells and normal cells are cocultured in vitro, and the tumor cell specificity of the polypeptide phages is tested; according to the testing results of polypeptide sequence and cell specificity, the polypeptide with tumor targeting is artifically synthesized. The invention as a specificity carrier of the mammary cancer-targeting genetic therapy has potential clinic application value. The invention also provides a strong technical support for the filtration of affinity specificity polypeptide of other types of malignant tumor cell strains. Moreover, the polypeptide only contains nine to eleven amino acid residues, so the polypeptide can be easily synthesized, the change of spacial position is relatively less, the quality control of the polypeptide is easy, and use is convenient.

The invention discloses a tumor homing cell-penetrating peptide tLyP-1 modified apoferritin nano-cage and a preparation method thereof. The protein nano-cage is hollow cage-shaped protein formed by self-assembling 24 protein subunits; and one tumor homing cell-penetrating peptide tLyP-1 is modified on an N end of each protein subunit by utilizing a gene recombination technology to obtain a recombinant human body heavy-chain ferritin nano-cage with a tLyP-1 modified surface. According to the protein nano-cage provided by the invention, a medicine is loaded into the nano-cage through adjusting depolymerization and recombination of the protein subunits; the nano-cage has good water solubility and biocompatibility, has excellent stability in a human body and has a uniform size; the nano-cage can be specifically combined with a lot of neuropilin receptors 1 (NRP-1) which are expressed in tumor neovascularization and tumor cells of malignant tumors including gliomas, breast cancer, pancreatic cancer, gastric cancer, colorectal cancer, non-small cell lung cancer and the like; and types of the tumors treated by the nano-cage are greatly increased and the targeting ability of tumor treatment is improved. The protein nano-cage provided by the invention has an extremely great application prospect in the aspects of tumor diagnosis and treatment and the like.

The invention discloses a simple method for detecting HLA-G and antibody thereof by gold-labeled immunoassay. The invention uses the monoclonal antibody of HLA-G and an HLA-G antigen fragment and / or HLA-G for successfully developing a gold-labeled immunity percolation analysis kit, and a gold-labeled immunochromatography sandwich method and competition method kit, which are used for the public to easily, rapidly and cheaply self-check and self-test the HLA-G in body fluid such as blood, saliva, urine, and the like so as to diagnose the early malignant tumor. In order to diagnose the earlier malignant tumor, a kit for detecting the HLA-G antibody by a gold-labeled immunochromatography indirect method is also developed and used for diagnosing the earlier malignant tumor. The kits are all called as 'broad-spectrum tumor diagnostic kit'. The invention aims at developing an easy, rapid and cheap 'broad-spectrum tumor diagnostic kit' for the self-check and self-test of the public so as to realize primary tumor screening and achieve the goal of finding and curing the tumor early, save the lives of the tumor patients, and reduce the tumor mortality.

The present invention relates to a medicine for curing malignant tumor and its preparation method. It is made of asparagus tuber, Buddha's hand fruit, American ginseng, acanthopanax obovatus, hippophae rhmnoides fruit, Chinese gooseberry root, venom and bolbostemma tuber as raw material through the processes of removing dust and cleaning, decocting, alcohol precipitation extraction and alcohol impregnating extraction. Said medicine has no toxic side effect, has strong action of resisting tumor and raising immunity of body, and can possess synergistic action and attenuation when it is matched with radiotherapy and chemical medicine therapy to cure malignant tumor, and can obtain good therapeutic effect.

The invention discloses a nitrile methyl piperazine derivative serving as a KRAS G12C mutant protein inhibitor and an application of the nitrile methyl piperazine derivative. The compound has a structure represented by a general formula (I). Compared with an existing compound, the compound provided by the invention has higher selectivity on malignant tumors caused by KRAS G12C mutation; a longer half-life period is shown, and better metabolic stability is achieved; the exposure amount is higher, the oral bioavailability is better, and the anti-tumor activity is more remarkable.

The invention relates to a method for preparing the nanometer target drug used to treat cancer. Wherein, it is a nanometer magnetic-antibody / ligand drug and nanometer magnetic target drug used in cancer magnetic thermal treatment, with high specific thermal power; it comprises 1:0.0001-0.20 effective molecule and guide molecule, while the effective molecule is magnetic powder whose diameter is lower than 1000nm, and the specific thermal power SAR is 10-7000W / gFe; the guide molecule comprises antibody or ligand or magnetic powder; the diameter of target drug is 2-1000nm; the preparation comprises that coupling the magnetic powder and guide molecule in water, organic or inorganic mixture. The inventive drug can effective kill cancer cell and treat cancer.

The invention relates to medical equipment and technology, especially the radioactive nano-coated steadier for the treatment of esophageal, airway and biliary tumors and its preparation method. The radioactive metal steadier applied in clinic at present are mainly used for the prevention of vascular restenosis after benign expansions, in the prevention and cure against the narrow cavity diseases caused by malignant tumor, there are still many problems. The invention develops radioactive nano-coated compound steadier by advanced nuclear and nano-technology technology. The original medical steadier was coated with a layer containing the isotope 125I nano composite film, with 300 to 900 radiation dose, less than 300 nm coating thickness. The invention not only has a supporting effect, but also has fistula prevention and radiation therapy effect. In a fairly long period of time to maintain the vascular flow, which not only improves the quality of life of patients but also prolong the patient's life.